Pfizer claims Metsera breached their merger agreement, adding that a tie-up of the biotech with GLP-1 drug giant Novo Nordisk ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The ...

Cell therapy developer Arcellx contends its lead program could be a safer alternative to currently available CAR T-treatments for multiple myeloma, noting that its previously reported preliminary data ...

Bayer’s Lynkuet, approved for treating moderate-to-severe vasomotor symptoms of menopause, targets two receptors key to ...

With federal PBM reform stalled, states like California are stepping up with laws like SB 41 to boost transparency and lower drug costs.

For a certain hormone deficiency inadequately managed with calcium and vitamin supplements, the only FDA-approved therapy is a daily injection that’s in limited supply and is set to exit the market ...

Advanced prostate cancer has a new treatment option, a Johnson & Johnson drug that combines two of the company’s therapies in a single pill. Niraparib is small molecule designed to block PARP, an ...

The expiration of ACA tax credits could drive up premiums across marketplace and commercial insurance plans, a Cigna executive warned.

The Trump administration’s recent changes to the H-1B visa application process are causing concern among healthcare experts, with many worried that the plan could make the industry’s workforce crisis ...

The use of AI in healthcare has evolved quite a bit over the past few years — with many healthcare organizations transitioning from a state of cautious experimentation to more serious attempts at ...

On Wednesday, Computer Programs and Systems, Inc. (CPSI) sold American HealthTech — its subsidiary that provides an EHR platform for the post-acute care market — to post-acute health IT vendor ...